Clinical Events. PROTIVA will notify ALNYLAM in writing within [**] of the dosing, respectively, of the first patient in a Phase II Clinical Trial and in a Phase III Clinical Trial for each PROTIVA Development Product.
Appears in 2 contracts
Samples: Cross License Agreement (Tekmira Pharmaceuticals Corp), Cross License Agreement (Alnylam Pharmaceuticals, Inc.)
Clinical Events. PROTIVA ALNYLAM will notify ALNYLAM PROTIVA in writing within [**] of the dosing, respectively, of the first patient in each of a Phase I Clinical Trial, a Phase II Clinical Trial Trial, and in a Phase III Clinical Trial for each PROTIVA ALNYLAM Development Product.
Appears in 2 contracts
Samples: Cross License Agreement (Tekmira Pharmaceuticals Corp), Cross License Agreement (Alnylam Pharmaceuticals, Inc.)
Clinical Events. PROTIVA will notify ALNYLAM in writing within [**] business days of the dosing, respectively, of the first patient in a Phase II Clinical Trial and in a Phase III Clinical Trial for each PROTIVA Development Product.
Appears in 1 contract
Samples: Cross License Agreement (TEKMIRA PHARMACEUTICALS Corp)